Randomized, double blind, placebo-controlled study to assess whether the administration of ramelteon could facilitate the discontinuation of zolpidem (Ambien) greater than or equal to 10 mg therapy in subjects with chronic insomnia.

Trial Profile

Randomized, double blind, placebo-controlled study to assess whether the administration of ramelteon could facilitate the discontinuation of zolpidem (Ambien) greater than or equal to 10 mg therapy in subjects with chronic insomnia.

Completed
Phase of Trial: Phase IV

Latest Information Update: 09 Jun 2013

At a glance

  • Drugs Ramelteon (Primary)
  • Indications Insomnia
  • Focus Therapeutic Use
  • Sponsors Takeda Global Research and Development Center
  • Most Recent Events

    • 30 Jan 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 23 Jan 2009 Actual end date (May 2008) added as reported by ClinicalTrials.gov.
    • 23 Jan 2009 Planned number of patients changed from 130 to 135 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top